文献速递主动脉疾病

术者改良开窗支架行胸主动脉腔内修复治疗主动脉弓病变的多中心回顾性研究

Thoracic Endovascular Repair for Aortic Arch Pathologies with Surgeon Modified Fenestrated Stent Grafts: A Multicentre Retrospective Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-10-08

这项多中心回顾性研究纳入7个中心连续513例主动脉弓病变患者,采用术者改良开窗支架行胸主动脉腔内修复(TEVAR)。技术成功率98.6%,30天临床成功率94.4%、生存率97.5%、免于再干预率97.1%;24个月分别为88.2%、94.9%、93.1%。结论认为该技术结局可接受,仍需进一步随访确认获益。

要点

  • 术者改良开窗支架行TEVAR治疗主动脉弓病变技术成功率98.6%。
  • 30天临床成功率94.4%,24个月降至88.2%。
  • 随访期记录18例卒中、6例逆行性A型主动脉夹层。

核心结论

  • 术者改良开窗支架行TEVAR治疗主动脉弓病变提供可接受的结局,仍需进一步随访确认该方法的获益。

研究设计与样本

  • 多中心回顾性研究,纳入7个中心连续513例接受术者改良开窗支架TEVAR治疗的主动脉弓病变患者,研究期间为2016年2月至2020年1月。
  • 研究应用一种使开窗与弓上血管对齐的技术,评估技术成功率、死亡率、并发症和再干预率。

主要发现

  • 技术成功率为98.6%(n=506),共创建626个开窗以重建684支主动脉弓分支动脉。
  • 术后30天内记录13例死亡和15例再干预。
  • 30天估计临床成功率为94.4%(95%CI 92.4-96.4),估计生存率为97.5%(95%CI 96.1-98.9),估计免于再干预率为97.1%(95%CI 95.7-98.5)。
  • 中位随访27个月(四分位距13-31),随访期间记录5例主动脉相关死亡、3例非主动脉相关死亡和4例原因不明死亡,18例患者接受再干预。
  • 24个月估计临床成功率为88.2%(95%CI 85.5-91.0),估计生存率为94.9%(95%CI 92.7-97.1),估计免于再干预率为93.1%(95%CI 91.0-95.3)。

关键数值与推荐

  • 共记录18例卒中,其中12例发生在30天内、6例发生在随访期间。
  • 共记录6例逆行性A型主动脉夹层,其中5例发生在30天内、1例发生在随访期间。

临床怎么用

  • 对于主动脉弓病变,术者改良开窗支架行TEVAR可作为提供可接受结局的治疗选择。
  • 术后需关注卒中及逆行性A型主动脉夹层等并发症,并进行再干预监测。
  • 需进一步随访确认该方法的长期获益。

局限性

  • 本研究为多中心回顾性研究。
  • 结论指出仍需进一步随访确认该方法的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the outcome of thoracic endovascular repair (TEVAR) for aortic arch pathologies with surgeon modified fenestrated stent grafts. METHODS: A multicentre, retrospective study consisting of consecutive patients from seven centres treated with surgeon modified fenestrated stent grafts for aortic arch pathologies was conducted. A technique to align fenestrations and supra-aortic vessels was applied. Rates of technical success, mortality, complications, and re-interventions were evaluated. RESULTS: Between February 2016 and January 2020, 513 consecutive patients with aortic arch pathologies received TEVAR with surgeon modified fenestrated stent grafts. The technical success rate was 98.6% (n = 506). In total, 626 fenestrations were created to revascularise 684 branch arteries of the aortic arch. There were 13 deaths and 15 re-interventions within 30 days of the operation. The estimated clinical success rate at 30 days was 94.4% (95% confidence interval [CI] 92.4 - 96.4), the estimated survival at 30 days was 97.5% (95% CI 96.1 - 98.9), and the estimated freedom from re-intervention at 30 days was 97.1% (95% CI 95.7 - 98.5). The median follow up was 27 (interquartile range 13 - 31) months. During follow up, there were five aortic related deaths, three non-aortic related deaths, and four deaths of unknown cause. Eighteen patients underwent re-intervention. The estimated clinical success rate at 24 months was 88.2% (95% CI 85.5 - 91.0), the estimated survival at 24 months was 94.9% (95% CI 92.7 - 97.1), and the estimated freedom from re-intervention at 24 months was 93.1% (95% CI 91.0 - 95.3). In total, 18 cases of stroke were recorded, including 12 within 30 days and six during follow up; six cases of retrograde type A aortic dissection were recorded, including five within 30 days and one during the follow up. CONCLUSION: TEVAR with surgeon modified fenestrated stent grafts for the treatment of aortic arch pathologies provides acceptable outcomes. Further follow up is required to confirm the benefits of this approach.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Li X, Li W, Dai X, et al. Thoracic Endovascular Repair for Aortic Arch Pathologies with Surgeon Modified Fenestrated Stent Grafts: A Multicentre Retrospective Study. Eur J Vasc Endovasc Surg. 2021. PMID: 34629276. doi:10.1016/j.ejvs.2021.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。